Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-06-04T18:07:37.479Z Has data issue: false hasContentIssue false
  • English
  • Français

Problems with Toxicity Studies in the Assessment of New Drugs

Published online by Cambridge University Press:  10 March 2009

Lars Werkö
Lars Werkö
Affiliation:
The Swedish Council for Technology Assessment in Health Care
Get access Rights & Permissions [Opens in a new window]

Abstract

The development of new medicines requires a lot of time and the efforts of many researchers. One of the most taxing parts of this endeavor is the need for long-term toxicity studies in different animals. This paper describes the development of two different medicines: zimeldine, an antidepressant, and omeprazole, a compound that acts against a specific enzyme in the gastric mucosa that is necessary for the production of gastric acid. Zimeldine was launched in the international market but had to be withdrawn when it caused severe unexpected adverse reactions. Omeprazole has been marketed successfully after a prolonged development phase characterized by difficult problems with the toxicity studies. Against the background of these two descriptions, this article questions the rationale for the present rules for long-term toxicity studies and emphasizes the need for leaders in the pharmaceutical industry to have a solid scientific background in order to be able to decide whether to abandon a project.

Type
Special Section: Industry and the Generation of Technology
Information
International Journal of Technology Assessment in Health Care , Volume 9 , Issue 2 , Spring 1993 , pp. 189 - 201
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Carlsson, A.The role of basic biomedical research in new drug development. In Gross, F., (ed.), Decision making in drug research. New York: Raven Press, 1983.Google Scholar
2.Carlsson, E.Pharmacology and toxicology of omeprazole. Scandinavian Journal of Gastroenterology, 1986, 118(suppl.), 31–38.CrossRefGoogle ScholarPubMed
3.Gross, F. (ed.). Decision making in drug research. New York: Raven Press, 1983.Google Scholar
4.Ogren, S. O., Ross, S. B., Hall, H., et al. The pharmacology of zimelidine: A 5-HT-selective re-uptake inhibitor. Acta Psychiatrica Scandinavica. 1981, 63(suppl. 290), 127–51.CrossRefGoogle Scholar
5.Sachs, G.The parietal cell as a therapeutic target. Scandinavian Journal of Gastroenterology, 1986, 118(suppl.), 1–10.CrossRefGoogle ScholarPubMed
6.Sundler, E., Carlsson, E., Hakanson, R., et al. Inhibition of gastric secretion by omeprazole and ranitidine. Scandinavian Journal of Gastroenterology, 1986, 118(suppl.), 39–45.CrossRefGoogle ScholarPubMed
7.Wallmark, B.Mechanism of action of omeprazole. Scandinavian Journal of Gastroenterology, 1986, 118(suppl.), 11–17. CrossRefGoogle ScholarPubMed